McDermott Will & Emery Advises Acticor Biotech on its Partnership with Mediolanum Farmaceutici

Overview


PARIS (November 23, 2016) – International law firm McDermott Will & Emery advised Acticor Biotech on its research collaboration agreement with Mediolanum Farmaceutici on Acticor’s project ACT-017, a humanized antibody fragment.

Under the terms of the agreement, Mediolanum will co-finance research and development of ACT-017, currently in preclinical development, as a potential next generation antithrombotic treatment for acute ischemic stroke.

Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for safe and effective emergency treatments of ischemic strokes. Acticor Biotech’s project stems from the need for new therapeutic options to manage stroke.

This project is based on academic research from Acticor Biotech founders, Dr. M. Jandrot-Perrus, Prof. P. Billiald and Dr. C. Gachet. It was supported by top institutions including the ANR (The French National Research Agency) and the Fondation de France, and won an Innovation Award from SGAM (Société Générale Asset Management).

The McDermott team advising on the transaction was comprised of Paris-based partners Emmanuelle Trombe and Anthony Paronneau.

McDermott’s Life Sciences Group works with clients to structure collaborative arrangements among emerging life sciences companies, established pharmaceutical and biotech companies and researchers and research institutions. These arrangements range from licensing technology to and from academic medical centers, universities and other research institutions, to complex strategic alliances among life sciences companies to achieve varied financial, research and development, manufacturing and distribution objectives. The Firm’s long-term experience in advising pharmaceuticals and agrochemical companies on taxation issues allows us to devise structures and tax plans for life sciences companies who wish to be attractive partners or acquisition candidates for the pharmaceutical industry.

About McDermott Will & Emery
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,000 lawyers, we have offices in Boston, Brussels, Chicago, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.